# Form Bio

> Form Bio is an Austin-based computational life sciences company that builds AI-driven software to speed up the design, characterization, and manufacturing of genetic medicines, especially adeno-associated virus (AAV) cell and gene therapies. Spun out of Colossal Biosciences in 2022 with a $30M Series A, its platform lets scientists model billions of therapeutic vector designs in silico to improve efficacy, safety, and manufacturability before ever entering the lab, targeting the manufacturing bottleneck that drives the majority of FDA rejections in the field.

- **Founded:** 2022
- **Headquarters:** Austin, Texas, United States
- **Founders:** Andrew Busey (Co-Founder & Co-CEO), Kent Wakeford (Co-Founder & Co-CEO), Ben Lamm (Co-Founder (also CEO of Colossal Biosciences))
- **Team size:** ~36 employees
- **Products:** FormManufacturing, FormSightAI (FORMsightAI), FormBatchQC, Computational platform / bioinformatics services
- **Notable:** Spun out of Colossal Biosciences in 2022 with an oversubscribed $30M Series A., Launched FORMsightAI in 2023, an AI solution set for predicting and optimizing cell & gene therapy manufacturability., Launched FormManufacturing, an end-to-end AI platform for design and manufacturing of genetic medicines, showcased at the ASGCT Annual Meeting.

## Products & services

- **FormManufacturing** — End-to-end platform to predict, optimize, and monitor manufacturability for cell & gene therapies, from initial construct design through commercial scale-up, integrating AI-driven design optimization with deep genomic characterization.
- **FormSightAI (FORMsightAI)** — AI solution set that screens thousands of vector constructs in silico to predict and optimize manufacturability, flagging risks such as partial capsids, host-cell contaminants, and CpG islands before they reach the lab.
- **FormBatchQC** — Lot-level analysis that quantifies genome integrity, detects impurities, and provides defensible regulatory evidence of lot-to-lot consistency from tech transfer through commercialization.
- **Computational platform / bioinformatics services** — Cloud-based data management, workflows, collaboration, and visualization tools for genomic data - including genome assembly and reconstruction, genome integrity analysis, AI-powered codon optimization, capsid analysis, and gene-editing support.

## Achievements

- Spun out of Colossal Biosciences in 2022 with an oversubscribed $30M Series A.
- Launched FORMsightAI in 2023, an AI solution set for predicting and optimizing cell & gene therapy manufacturability.
- Launched FormManufacturing, an end-to-end AI platform for design and manufacturing of genetic medicines, showcased at the ASGCT Annual Meeting.
- Attracted marquee gene therapy customers including Taysha, Solid Biosciences, and Coave Therapeutics.

## Latest updates

- **2026-05** — Launched FormManufacturing, an end-to-end platform for AI-driven design and manufacturing of genetic medicines, and showcased it at the ASGCT Annual Meeting in Boston.
- **2023-05** — Announced FORMsightAI, an AI solution set for predicting and optimizing cell & gene therapy manufacturability.
- **2022-09** — Spun out of Colossal Biosciences with a $30M Series A led by JAZZ Venture Partners.

## Links

- Website: https://formbio.com
- LinkedIn: http://www.linkedin.com/company/formbio
- Twitter/X: https://twitter.com/form_bio
- Facebook: https://facebook.com/formbio

---

Profile page: https://yespress.io/form-bio
Published by YesPress — https://yespress.io
Last updated: 2026-07-21